Jacobs Levy Equity Management
RNAC icon

Jacobs Levy Equity Management’s Cartesian Therapeutics RNAC Stock Holding History

Jacobs Levy Equity Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-101,534
Closed -$624K – 1054
2026
Q1 		$624K Buy
101,534
+5,735
+6% +$40.9K ﹤0.01% 786
2025
Q4 		$691K Buy
95,799
+65,798
+219% +$532K ﹤0.01% 747
2025
Q3 		$307K Sell
30,001
-11,316
-27% -$127K ﹤0.01% 879
2025
Q2 		$429K Buy
+41,317
New +$440K ﹤0.01% 904
2023
Q4 		– Sell
-1,083
Closed -$34.4K – 1066
2023
Q3 		$34.4K Sell
1,083
-12,694
-92% -$424K ﹤0.01% 950
2023
Q2 		$463K Sell
13,777
-3,923
-22% -$140K ﹤0.01% 834
2023
Q1 		$738K Sell
17,700
-5,837
-25% -$274K ﹤0.01% 751
2022
Q4 		$798K Sell
23,537
-497
-2% -$21.1K 0.01% 714
2022
Q3 		$1.18M Sell
24,034
-7,012
-23% -$385K 0.01% 674
2022
Q2 		$1.22M Sell
31,046
-5,980
-16% -$177K 0.01% 714
2022
Q1 		$1.37M Sell
37,026
-21,792
-37% -$1.36M 0.01% 702
2021
Q4 		$5.75M Sell
58,818
-8,043
-12% -$865K 0.04% 401
2021
Q3 		$8.34M Sell
66,861
-7,144
-10% -$863K 0.06% 337
2021
Q2 		$9.28M Buy
74,005
+4,639
+7% +$552K 0.06% 311
2021
Q1 		$9.42M Buy
69,366
+33,048
+91% +$4.1M 0.07% 300
2020
Q4 		$3.3M Buy
36,318
+26,581
+273% +$2.3M 0.03% 475
2020
Q3 		$724K Buy
9,737
+1,664
+21% +$127K 0.01% 722
2020
Q2 		$688K Buy
8,073
+6,886
+580% +$624K 0.01% 736
2020
Q1 		$86K Buy
+1,187
New +$115K ﹤0.01% 963
2019
Q1 		– Sell
-2,775
Closed -$221K – 1027
2018
Q4 		$221K Buy
2,775
+216
+8% +$49.3K ﹤0.01% 856
2018
Q3 		$1.19M Buy
2,559
+20
+0.8% +$8.04K 0.02% 619
2018
Q2 		$1.01M Buy
+2,539
New +$901K 0.02% 663

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management's RNAC Position: Q2 2026 in Review

Jacobs Levy Equity Management sold out of Cartesian Therapeutics (RNAC) in Q2 2026, closing a stake of 101,534 shares — an estimated $624K sold.

Jacobs Levy Equity Management first reported a position in RNAC in Q2 2018 and held it in 22 quarters. The position peaked at $9.42M in Q1 2021. 94 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Jacobs Levy Equity Management reported no remaining Cartesian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 101,534 Cartesian Therapeutics shares in Q2 2026, an estimated $624K.
  • Jacobs Levy Equity Management first reported a position in Cartesian Therapeutics in Q2 2018 and held it in 22 quarters.
  • Jacobs Levy Equity Management's Cartesian Therapeutics position peaked at $9.42M in Q1 2021.
  • 94 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.